write an application to messors gupta son's gupta pharmaceutical industrial area for the post of marketing representative in their firm.
Answers
Explanation:
are under serious pressure.
North America, Europe and Japan jointly
account for 82% of audited and
unaudited drug sales; total sales
reached US$773 billion in 2008,
according to IMS Health. Annual growth
in the European Union (EU) has slowed
to 5.8%, and sales are increasing at an
even more sluggish rate in Japan (2.1%)
and North America (1.4%).1
Impending
policy changes, promoting the use of
generics in these key markets are
expected to further dent the top- and
bottom-line of global pharma majors.
The industry is bracing itself for some
fundamental changes in the
marketplace and is looking at newer
ways to drive growth.
Further, higher R&D costs, a relatively
dry pipeline for new drugs, increasing
pressure from payers and providers for
reduced healthcare costs and a host of
other factors are putting pressure on the
global pharmaceutical companies.
Pharma companies are looking for new
ways to boost drug discovery potential,
reduce time to market and squeeze
costs along the whole value chain.
How can industry leaders best face
these challenges? Analysis by
PricewaterhouseCoopers (PwC) shows
that several regions offer considerable
promise, either as places with untapped
demand for effective drugs or as
suitable areas for conducting research
and development (R&D) and/or clinical
trials. In this paper we shall examine the
opportunities available in India.
India’s population is growing rapidly, as
is its economy – creating a large middle
class with the resources to afford
Western medicines. Further, India’s
epidemiological profile is changing, so
demand is likely to increase for drugs
for cardio-vascular problems, disorders
of the central nervous system and other
chronic diseases. Together these factors
mean that India represents a promising
potential market for global
pharmaceutical manufacturers.
More than that, India has a growing
pharmaceutical industry of its own. It is
likely to become a competitor of global
pharma in some key areas, and a
potential partner in others. India has
considerable manufacturing expertise;
Indian companies are among the world
leaders in the production of generics
and vaccines. As both of these areas
become more important, Indian
producers are likely to take a large role
on the world stage – and potentially
partner with global pharma companies
to market their wares outside of India.
Indian companies have also started
entering into the realm of R&D; some of
the leading local producers have now
started conducting original research.
India has the world’s second biggest
pool of English speakers and a strong
system of higher education, so it should
be well-positioned to serve as a source
for research talent. A new patent regime
provides better protection of intellectual
property rights, although some issues
remain. Clinical trials can also be
conducted here much more cost-
effectively than in many developed
nations, and some local companies are
beginning to develop the required
expertise. All of these factors add up to
a strong case for partnering with Indian
companies around R&D, including
clinical testing.
Further, healthcare has become one of
the key priorities of the Indian
Government and it has launched new
policies and programmes to boost
local access and affordability to
quality healthcare.
Global players in the pharma industry